Preserved T-cell response in anti-CD20-treated multiple sclerosis patients following SARS-CoV-2 vaccination.

Simon FaissnerNeele HeitmannRicarda RohlingUlas CeylanMarielena BongertCarlos Plaza-SirventCorinna MarheineckeXiomara PedreiturriaIlya AyzenbergKerstin HellwigIngo SchmitzStephanie PfaenderRalf Gold

Published in: Therapeutic advances in neurological disorders (2022)

In summary, aCD20-treated patients have a reduced humoral immune response, depending on B cell repopulation, in accordance with preserved cellular immune response, suggesting partial cellular protection against SARS-CoV-2.

Keyphrases

immune response
sars cov
newly diagnosed
multiple sclerosis
end stage renal disease
ejection fraction
toll like receptor
nk cells